Use of replicating oncolytic adenoviruses in combination therapy for cancer

Roland L. Chu, Dawn E. Post, Fadlo R. Khuri, Erwin G. Van Meir

Research output: Contribution to journalReview articlepeer-review

135 Scopus citations


Oncolytic virotherapy is the use of genetically engineered viruses that specifically target and destroy tumor cells via their cytolytic replication cycle. Viral-mediated tumor destruction is propagated through infection of nearby tumor cells by the newly released progeny. Each cycle should amplify the number of oncolytic viruses available for infection. Our understanding of the life cycles of cytolytic viruses has allowed manipulation of their genome to selectively kill tumor cells over normal tissue. Because the mechanism of tumor destruction is different, oncolytic virotherapy should work synergistically with current modes of treatment such as chemotherapy and radiation therapy. This article focuses on oncolytic adenoviruses that have been created and tested in preclinical and clinical trials in combination with chemotherapy, radiation therapy, and gene therapy.

Original languageEnglish
Pages (from-to)5299-5312
Number of pages14
JournalClinical Cancer Research
Issue number16
StatePublished - Aug 15 2004


Dive into the research topics of 'Use of replicating oncolytic adenoviruses in combination therapy for cancer'. Together they form a unique fingerprint.

Cite this